Fitzsimons Innovation Community is an integrated urban campus where health and life sciences companies of all sizes work on their next big things. Our customized workspace, collaborative campus, and proximity to one of the top health systems and medical schools in the country make our community the perfect place to put down roots and get to work.
MOVE-IN READY LAB SPACE
GROWTH OPPORTUNITIES
It’s not just additional space—it’s fifty sprawling acres of additional space. And it’s primed for ultra-custom, made-to-order facility development.
Fitzsimons Innovation Community and University of Colorado Anschutz Medical Campus working together.
Relationships that help you thrive.
FEATURED:
One of the most exciting times of year for us here at Fitzsimons Innovation Community is when we launch our Annual Innovation Report, and this year is no different. For the fourth year in a row, we are proud to share this report featuring updates, insight, and data about all the things that make our Community special.
Fitzsimons Innovation Community is where innovators come to turn ideas into business.
A monthly feature of a Fitzsimons Innovation Community visionary.
Our year in innovation.
Find out what’s happening on campus and across the industry.
An urban mountain lifestyle for work and play.
Everything you need.
Right here.
Read Fitzsimons Innovation Community news, industry highlights, editorials, and innovation updates happening weekly on our campus.
Fitzsimons Innovation Community, a thriving hub where researchers, practitioners, educators, and innovators collaborate to bring life-changing healthcare solutions to patients, announced the appointment of Kenneth Ho as chief operating officer. A highly respected real estate developer with more than 25 years of experience, Ho will play a pivotal role in bringing the Community’s ambitious Master Plan to life.
A real estate developer with more than 25 years of experience has been appointed as the new chief operating officer of the Fitzsimons Innovation Community in Aurora. Kenneth Ho, the new COO, will play a pivotal role in bringing the community’s master plan to life. Ho has over two decades of experience in real estate development, investment and planning, with a specialization in complex, mixed-use communities.
Fitzsimons Innovation Community, a thriving hub where researchers, practitioners, educators, and innovators collaborate to bring life-changing healthcare solutions to patients, announces the appointment of Kenneth Ho as Chief Operating Officer. A highly respected real estate developer with more than 25 years of experience, Ho will play a pivotal role in bringing the Community’s ambitious Master Plan to life.
GelSana Therapeutics, Inc. has been selected to join the 2025 MedTech Innovator cohort, the world’s largest accelerator for medical device companies. GelSana is one of only 65 companies—representing the top 4% of nearly 1,500 global applicants—chosen for this year’s program. This recognition reflects the incredible work of our team and validates the potential of our solution to make a meaningful impact on healthcare.
Colorado Hub for Health Impact, the national economic development campaign positioning Colorado as an epicenter for health innovation, launches its 2025 campaign with new partner investment and a clear focus: attract life sciences companies, talent, and investors to a community that elevates science.
Aurora City Council has approved a massive increase in allowable housing at Fitzsimons Innovation Community, a move intended to transform the bioscience campus into a full-fledged neighborhood. Fitzsimons CEO Kelly Brough called the change “an obligation” to honor the site’s history while shaping a future that attracts talent and builds community.
A change to the Fitzsimons Innovation Community’s master plan in Aurora will allow eight times more residential units to be built on the medical campus.The Aurora City Council on Monday approved an amendment to the general development plan that increases the Fitzsimons Innovation Community residential unit cap from 850 units to 7,266 new units. Changes also include improvements to street, utility, drainage, parks and open space on site. Kelly Jean Brough, President and CEO of Fitzsimons Innovation Community, said the change will bring together the grander vision of a more interconnected campus.
The University of Colorado Cancer Center this year celebrates its 40th anniversary, highlighting significant advances in research and innovations that include new therapies, treatments and insights into cancer prevention. One of the leaders in cell-based immune therapies is CU Cancer Center member Terry Fry, M.D., executive director of the Gates Institute, a translational research institute on the CU Anschutz Medical Campus that produces CAR T and other cellular therapies for research. Gates recently launched a clinical trial of a CAR for pediatric patients with relapsed or refractory pre B-cell acute lymphoblastic leukemia (B-ALL).
As Fitzsimons Innovation Community celebrates the 25th anniversary, President and CEO Kelly Brough reflects on a remarkable journey of transformation—and an even more ambitious vision for the future. What began as a bioscience incubation campus has evolved into something unprecedented: a thriving ecosystem where researchers, practitioners, educators, and innovators collaborate to bring life-changing healthcare solutions directly to patients.
A new approach for gene editing will get its shot in a common and chronic autoimmune disorder. Rheumatoid arthritis is an autoimmune disease that causes pain and swelling in the joints. It affects about one percent of the adult population. With its HLA gene editing approach, RheumaGen believes it can create a one-time cure for rheumatoid arthritis that solves for uncontrolled disease and ineffective therapies.
A startup is developing a new class of treatments for autoimmune diseases leveraging an approach to editing genes in the HLA family, which play a critical role in the immune system. RheumaGen, which spun out from the University of Colorado Anschutz Medical Campus, launched earlier this year with $15 million in Series A funding co-led by investment firms SPRIM Global Investments and William Taylor Nominees. The company focuses on autoimmune conditions with genetic risk factors linked with certain variants in HLA genes.
This year, Fitzsimons Innovation Community is proudly celebrating 25 years of innovation since the grand opening of Bioscience 1 in 2000. For every one of those 25 years—and many before that—Lyle Artz, Site Manager of Fitzsimons Innovation Community, has been here. We were honored to sit down with him and discuss the history, logistics, collaboration, and hard work involved in the early days of the redevelopment of the campus and how all of those elements are still part of the Fitzsimons Innovation Community fabric 25 years later.
Fitzsimons Innovation Community
